Abstracts tagged "Lipids"

Abstract Number: 1115 • 2016 ACR/ARHP Annual Meeting
Non-Esterified Fatty Acids Are Associated with Clinical Features and an Enhanced Th1 Response in Rheumatoid Arthritis: Towards Disease Profiling
Javier Rodríguez-Carrio¹, Mercedes Alperi-López², Patricia López¹, Francisco Javier Ballina-García² and Ana Suárez¹, ¹Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ²Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain
Background/Purpose: Non-Esterified Fatty Acids (NEFA) are important lipid mediators which can play a role in a number of biological functions other than energy supply. NEFA…
Abstract Number: 1125 • 2016 ACR/ARHP Annual Meeting
Targeted Lipidomics Reveals Incomplete Activation of Resolution Pathways in Knee Osteoarthritis
Hulda Jonasdottir¹, Hilde Brouwers², Mukundan Attur³, Joanneke Kwekkeboom², Jonathan Samuels³, Eric Strauss⁴, Enrike van der Linden-van der Zwaag⁵, TWJ Huizinga⁶, M. Kloppenburg⁷, REM Toes⁸, Martin Giera⁹, Steven B. Abramson³ and Andreea Ioan-Facsinay², ¹Center for Proteomics and Metabolomics, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Medicine, NYU School of Medicine, NYU Langone Medical Center, New York, NY, ⁴Department of Orthopedic Surgery, NYU School of Medicine, NYU Langone Medical Center, New York, NY, ⁵Department of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Centre, Leiden, Netherlands, ⁷Rheumatology and Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Persistent inflammation is a characteristic of several joint diseases, including OA. It is nowadays appreciated that this could be a result of a failure…
Abstract Number: 1434 • 2016 ACR/ARHP Annual Meeting
Effect of Systemic and Local Inflammation on the Insulin Resistance and Glucose/Lipid Metabolism in Rheumatoid Arthritis: Humans and CIA Mouse Model
Nuria Barbarroja¹, IVÁN ARIAS DE LA ROSA¹, Manuel Peña¹, Sergio Rodriguez-Cuenca², Yolanda Jiménez-Gómez¹, Patricia Ruiz-Limon³, Carlos Perez-Sanchez¹, Maria Carmen Abalos-Aguilera³, Jerusalem Calvo-Gutierrez¹, Eduardo Collantes-Estévez¹, Antonio Vidal-Puig², Chary Lopez-Pedrera¹ and Alejandro Escudero-Contreras¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbroke’s Hospital, University of Cambridge, Cambridge, United Kingdom, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients are at higher risk for insulin resistance (IR). The association between RA and IR, and its role on the different…
Abstract Number: 1480 • 2016 ACR/ARHP Annual Meeting
Determination of the Lipid Profile in Active Disease Leads to Incorrect Cardiovascular Risk Prediction in Early Rheumatoid Arthritis Patients
Samina A. Turk¹, Dirkjan van Schaardenburg^1,2, Willem F. Lems^1,3 and Mike T. Nurmohamed^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity and mortality. This cardiovascular risk is mainly determined by the lipid profile, which may change…
Abstract Number: 1490 • 2016 ACR/ARHP Annual Meeting
Metabolic and Cardio-Vascular Benefits of Hydroxychloroquine in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Claire Rempenault¹, Thomas Barnetche², Jacques Morel³, Cédric Lukas⁴, Cécile Gaujoux-Viala⁵, Bernard Combe⁶ and Charlotte Hua⁷, ¹Rheumatology, CHU Lapeyronie, University of Montpellier, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA) patients. Hydroxychloroquine (HCQ) has been shown to improve major outcomes like…
Abstract Number: 1495 • 2016 ACR/ARHP Annual Meeting
Lipoprotein(a) Concentrations in Rheumatoid Arthritis on Biologic Therapy: Results from the Cardiovascular in Rheumatology [CARMA] Study Project
Maria Carmen Garcia-Gomez¹, Maria Auxiliadora Martin², Santos Castañeda³, Fernando Sánchez-Alonso⁴, Miren Uriarte Ecenarro⁵, Carlos González-Juanatey⁶, Romera-Baures Monserrat⁷, Santos-Rey Jose⁸, Jose A Pinto-Tasende⁹, Estefania QuesadaMasachs¹⁰, Jesús Tornero¹¹, Olga Martínez González¹², Tatiana Cobo-Ibáñez¹³, Eugenio Chamizo Carmona¹⁴, Sara Manrique-Arija¹⁵, Dolores Fábregas-Canales¹⁶, Federico Díaz-González¹⁷, Javier Llorca¹⁸, Miguel Angel González-Gay¹⁹ and CARMA Collaborative Group, ¹Rheumatology, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ⁴Research Unit of Spanish Society of Rheumatology, Madrid, Spain, ⁵Donostia University Hospital, San Sebastian, Spain, ⁶Division or Cardiology, Hospital Lusus Augusti, Lugo, Spain, ⁷Rheumatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Spain, ⁸Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ⁹Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ¹⁰Rheumatology, Hospital Universitari Vall d’Hebron, Barcelona, Spain, ¹¹Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ¹²Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ¹³Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹⁴Rheumatology, Hospital de Mérida, Mérida, Spain, ¹⁵Rheumatology, Hospital Carlos Haya, Malaga, Spain, ¹⁶Rheumatology, Hospital de Barbastro, Barbastro (Huesca), Spain, ¹⁷Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ¹⁸Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain
Background/Purpose: Plasma concentrations of lipoprotein (a) [Lp(a)], a lipoprotein with proatherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have…
Abstract Number: 3023 • 2016 ACR/ARHP Annual Meeting
Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies
Iain B. McInnes¹, Joel Kremer², Paul Emery³, Steven H. Zuckerman⁴, Giacomo Ruotolo⁴, Chadi Saifan⁴, Lei Chen⁴, Shayami Thanabalasundrum⁴, Sarah Witt⁴ and William Macias⁴, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain, ²The Center for Rheumatology, Albany Medical College, Albany, NY, ³University of Leeds, Midlothian, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: In patients with active RA an increase in lipid analytes has been observed after treatment with janus kinase inhibitors and other disease-modifying antirheumatic drugs.1…
Abstract Number: 69 • 2016 ACR/ARHP Annual Meeting
IL-32 Promoter SNP rs4786370 Predisposed to Modified Lipoprotein Profiles in Patients with Rheumatoid Arthritis
Michelle S.M.A. Damen¹, Rabia Agca², Suzanne Holewijn³, Jacqueline de Graaf¹, Jéssica C. Dos Santos^1,4, Piet L van Riel⁵, J Fransen⁶, Marieke J.H. Coenen⁷, Mike T. Nurmohamed⁸, M.G. Netea¹, Charles Dinarello⁹, L.A.B. Joosten¹, Bas Heinhuis¹ and Calin Popa¹⁰, ¹Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, Location Reade, Amsterdam, Netherlands, ³Rijnstate Ziekenhuis, Arnhem, Netherlands, ⁴Instituto de Patologia Tropical e Saúde Pública, Goiás, Brazil, ⁵Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, Netherlands, ⁶Department of Rheumatolgy, Radboud UMC, Nijmegen, Netherlands, ⁷Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁹Department of Medicine, Division of Infectious Diseases, University of Colorado, Denver, CO, ¹⁰Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Patients with a chronic inflammatory disease such as rheumatoid arthritis (RA) are at higher risk of developing cardiovascular diseases (CVD). Interleukin (IL)-32 has previously…
Abstract Number: 115 • 2015 ACR/ARHP Annual Meeting
Validation of a Large Rheumatoid Arthritis Cohort and Preventive Health Screening
Michael Grasso¹, Dana Direnzo², Yelena Yesha³, Naphtali Rishe⁴ and Amanda Niskar⁵, ¹Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, ²Internal Medicine, University of Maryland Medical Center, Baltimore, MD, ³Computer Science and Electrical Engineering, Professor, Baltimore, MD, ⁴Computer Science, Florida International University, Miami, FL, ⁵1330 West Peachtree Street NW, Arthritis Foundation, Atlanta, GA
Background/Purpose: We extracted a large cohort of rheumatoid arthritis (RA) patients, on which we plan to apply big data analytics for earlier diagnosis of RA.…
Abstract Number: 131 • 2015 ACR/ARHP Annual Meeting
Frequency of Lipid Testing and Management Among Rheumatoid Arthritis Patients Compared to the General Population and Patients with Diabetes
Iris Navarro-Millan¹, Shuo Yang², Monica Safford³, Lang Chen³, Huifeng Yun⁴ and Jeffrey R. Curtis³, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA) have high coronary heart disease (CHD) burden and accelerated atherosclerotic status. However, limited data suggest that these patients may…
Abstract Number: 133 • 2015 ACR/ARHP Annual Meeting
Advocating for Rheumatoid Arthritis and Cardiovascular Health (ARCH) in a Tertiary Referral Center: A Collaborative and Systems-Based Approach to Improve Access to Care
Barbara Goldstein¹, JoAnn Zell¹, Pearlanne Zelarney², Matthew Stern², Sarah Meadows², Meg Dingae², Carmen Egidio² and Darlene Kim², ¹Medicine, National Jewish Health, Denver, CO, ²National Jewish Health, Denver, CO
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease (CVD) as compared to the general population. The European League Against Rheumatism…
Abstract Number: 496 • 2015 ACR/ARHP Annual Meeting
Increased Serum Lipids Under Tocilizumab Is Not Influenced By Methotrexate
Manfred Herold¹, Peter Fasching², Winfried Graninger³, Raimund Lunzer⁴, Omid Zamani⁵ and Burkhard Leeb⁶, ¹Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ²Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ³Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁵Rheumazentrum Favoriten Vienna, Wien, Austria, ⁶2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria
Background/Purpose: Increased serum lipid levels in patients being treated with tocilizumab (TCZ) is known from several clinical trials1,2. It is not known whether additional methotrexate…
Abstract Number: 1506 • 2015 ACR/ARHP Annual Meeting
EULAR Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Inflammatory Joint Diseases – 2015 Update
Michael T. Nurmohamed and on behalf of the EULAR task force "EULAR Recommendations for Cardiovascular Risk Management in patients with Rheumatoid Arthritis and other Inflammatory Joint Diseases", Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) (and other inflammatory joint diseases (IJD)) have an increased cardiovascular (CV) risk. In 2009 a EULAR taskforce recommended screening,…
Abstract Number: 1539 • 2015 ACR/ARHP Annual Meeting
Control of Modifiable Cardiovascular Risk Factors in Rheumatoid Arthritis Patients Compared to Traditional High-Risk Cardiovascular Disease Patients
Brian LaMoreaux¹, Alexa Meara² and Wael N. Jarjour³, ¹Rheumatology, The Ohio State University, Columbus, OH, ²Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ³Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease affecting one percent of the population. The main cause of mortality among RA patients…
Abstract Number: 1563 • 2015 ACR/ARHP Annual Meeting
Dyslipidemia and Hyperglycemia, Two Cardiometabolic Parameters, Independently Predict Poor Outcome in Early Rheumatoid Arthritis: Results from Espoir Cohort
Claire I. Daien¹, Jeremie Sellam², Nathalie Rincheval³, Bruno Fautrel⁴, Alain Saraux⁵, Francis Berenbaum⁶, Jacques Morel¹, Jean-Pierre Daures⁷ and Bernard Combe⁸, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Department of Rheumatology, Assistance Publique – Hôpitaux de Paris, Saint-Antoine Hospital, Paris, France, ³Biostatistic, EA 2415, Epidemiology unit, Montpellier, France, ⁴Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶Rheumatology and Paris VI University, Saint-Antoine Hospital, Paris, France, ⁷Biostatistic, EA 2415 Epidemiology unit, Montpellier, France, ⁸Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Previous studies showed that obesity in patients with rheumatoid arthritis (RA) is associated with higher disease activity. Beyond obesity, cardiometabolic disturbances may impact the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].